IL104063A0 - Methods and compositions for reducing multi-drug resistance - Google Patents

Methods and compositions for reducing multi-drug resistance

Info

Publication number
IL104063A0
IL104063A0 IL104063A IL10406392A IL104063A0 IL 104063 A0 IL104063 A0 IL 104063A0 IL 104063 A IL104063 A IL 104063A IL 10406392 A IL10406392 A IL 10406392A IL 104063 A0 IL104063 A0 IL 104063A0
Authority
IL
Israel
Prior art keywords
compositions
methods
drug resistance
reducing multi
reducing
Prior art date
Application number
IL104063A
Other languages
English (en)
Original Assignee
Rush Presbyterian St Luke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush Presbyterian St Luke filed Critical Rush Presbyterian St Luke
Publication of IL104063A0 publication Critical patent/IL104063A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL104063A 1991-12-10 1992-12-10 Methods and compositions for reducing multi-drug resistance IL104063A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80518691A 1991-12-10 1991-12-10
US98276692A 1992-12-07 1992-12-07

Publications (1)

Publication Number Publication Date
IL104063A0 true IL104063A0 (en) 1993-05-13

Family

ID=27122756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL104063A IL104063A0 (en) 1991-12-10 1992-12-10 Methods and compositions for reducing multi-drug resistance

Country Status (8)

Country Link
EP (1) EP0616493A4 (fr)
JP (1) JPH07502274A (fr)
CN (1) CN1076358A (fr)
AU (1) AU3243393A (fr)
CA (1) CA2125279A1 (fr)
IL (1) IL104063A0 (fr)
MX (1) MX9207150A (fr)
WO (1) WO1993011668A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
CA2130025A1 (fr) * 1993-08-25 1995-02-26 Robert B. Peery Methode de traitement des infections fongiques
AU2689495A (en) * 1994-05-19 1995-12-18 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
KR20020000147A (ko) * 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
WO2000067802A1 (fr) * 1999-05-10 2000-11-16 Protarga, Inc. Compositions d'acides gras -n-substituted indol-3-glyoxyl-amide et leur utilisation
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4889525A (en) * 1982-08-17 1989-12-26 Adamantech, Inc. Sensitization of hypoxic tumor cells and control of growth thereof
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4978622A (en) * 1986-06-23 1990-12-18 Regents Of The University Of California Cytophaga-derived immunopotentiator
JP2558107B2 (ja) * 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US4863968A (en) * 1987-04-09 1989-09-05 Merrell Dow Pharmaceuticals Inc. Methods of treating gout with chalcone derivatives
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair

Also Published As

Publication number Publication date
MX9207150A (es) 1993-12-01
AU3243393A (en) 1993-07-19
CN1076358A (zh) 1993-09-22
CA2125279A1 (fr) 1993-06-24
EP0616493A4 (fr) 1994-11-09
JPH07502274A (ja) 1995-03-09
WO1993011668A1 (fr) 1993-06-24
EP0616493A1 (fr) 1994-09-28

Similar Documents

Publication Publication Date Title
GB2294465A8 (en) Perfluoroelastomeric compositions and methods
IL104107A0 (en) New compounds and compositions
GB9121289D0 (en) Composition and use
EP0540357A3 (en) Protein-silicone copolymers and compositions containing them
NZ268969A (en) Morphinan derivatives and pharmaceutical compositions
KR950013580B1 (en) Method and compositions for difusion patierning
IL101281A0 (en) Anti-cancer compounds and compositions
SG42865A1 (en) Therapeutic compositions and methods
EP0499233A3 (en) Organopentasiloxane and method for its preparation
ZA921279B (en) Substituted alpha-aminoaldehydes and derivatives
EP0510591A3 (en) Polymer compositions and their blends
IL104063A0 (en) Methods and compositions for reducing multi-drug resistance
ZA943649B (en) Piperidine derivatives their preparation and use
GB8922701D0 (en) Compositions and methods for weight reduction
ZA924491B (en) Compositions and use thereof
ZA921137B (en) Composition and use
GB9224295D0 (en) Method and composition
ZA929596B (en) Methods and compositions for reducing multi-drug resistance.
IL113542A0 (en) Substituted hydroxybenzyl-heteroaryl derivatives compositions containing them and their use
ZA922146B (en) Inorganic perbromide compositions and methods for use thereof
GB9026896D0 (en) Method and composition
GB9111824D0 (en) Method and composition
GB9308051D0 (en) Method and composition
GB9116906D0 (en) Composition and use
GB9108646D0 (en) Pharmaceutical method and compositions